CN107635990A - 新型3‑吲哚取代的衍生物、药物组合物及使用方法 - Google Patents

新型3‑吲哚取代的衍生物、药物组合物及使用方法 Download PDF

Info

Publication number
CN107635990A
CN107635990A CN201680028408.7A CN201680028408A CN107635990A CN 107635990 A CN107635990 A CN 107635990A CN 201680028408 A CN201680028408 A CN 201680028408A CN 107635990 A CN107635990 A CN 107635990A
Authority
CN
China
Prior art keywords
fluoro
indol
isothiazole
methyl
yls
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680028408.7A
Other languages
English (en)
Chinese (zh)
Inventor
S·宁科维奇
S·克罗西尼亚尼
S·A·斯凯尔斯
I·J·麦卡尔平
M·R·柯林斯
A·马代尔纳
M·威思
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kuyt Medical Oswald
Pfizer Inc
Original Assignee
Kuyt Medical Oswald
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2015/051957 external-priority patent/WO2015140717A1/en
Application filed by Kuyt Medical Oswald, Pfizer Inc filed Critical Kuyt Medical Oswald
Publication of CN107635990A publication Critical patent/CN107635990A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201680028408.7A 2015-03-17 2016-03-17 新型3‑吲哚取代的衍生物、药物组合物及使用方法 Pending CN107635990A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IBPCT/IB2015/051957 2015-03-17
PCT/IB2015/051957 WO2015140717A1 (en) 2014-03-18 2015-03-17 Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
US201562203032P 2015-08-10 2015-08-10
US62/203,032 2015-08-10
PCT/IB2016/051509 WO2016147144A1 (en) 2015-03-17 2016-03-17 Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use

Publications (1)

Publication Number Publication Date
CN107635990A true CN107635990A (zh) 2018-01-26

Family

ID=56919874

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680028408.7A Pending CN107635990A (zh) 2015-03-17 2016-03-17 新型3‑吲哚取代的衍生物、药物组合物及使用方法

Country Status (14)

Country Link
US (1) US9873690B2 (enExample)
EP (1) EP3271354A1 (enExample)
JP (1) JP6775516B2 (enExample)
KR (1) KR102013512B1 (enExample)
CN (1) CN107635990A (enExample)
AU (1) AU2016231832B2 (enExample)
BR (1) BR112017019699A2 (enExample)
CA (1) CA2979616C (enExample)
HK (1) HK1243999A1 (enExample)
IL (1) IL254124A0 (enExample)
MX (1) MX2017011951A (enExample)
RU (1) RU2672252C1 (enExample)
SG (1) SG11201706992TA (enExample)
WO (1) WO2016147144A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111166735A (zh) * 2020-01-15 2020-05-19 延边大学 邻苯二甲酸-双-(2-乙基庚基)酯在抑制脂肪蓄积中的应用
CN111499592A (zh) * 2020-03-14 2020-08-07 江苏省农用激素工程技术研究中心有限公司 5-氨甲基糖精的合成方法
CN111777557A (zh) * 2020-07-28 2020-10-16 中国科学院上海有机化学研究所 以芳香联苯烯为骨架的新型抗肿瘤先导化合物及其应用
WO2021218912A1 (zh) * 2020-04-30 2021-11-04 南京明德新药研发有限公司 含苯基并内磺酰胺的化合物
CN119707855A (zh) * 2024-12-20 2025-03-28 西南大学 一种光学活性胺类衍生物及其不对称烷基化合成方法和应用

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160336813A1 (en) 2015-05-15 2016-11-17 NeuSpera Medical Inc. Midfield coupler
CA3172446A1 (en) 2014-05-18 2015-11-26 NeuSpera Medical Inc. Midfield coupler
AU2016263808B2 (en) 2015-05-21 2019-01-03 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2018115984A1 (en) 2016-12-19 2018-06-28 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation
IL300964A (en) 2017-05-12 2023-04-01 Harpoon Therapeutics Inc mesothelin binding proteins
AU2018277559A1 (en) 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-LAG-3 antibody, a PD-1 pathway inhibitor, and an immunotherapeutic agent
FI3694529T3 (fi) 2017-10-13 2024-09-17 Harpoon Therapeutics Inc Trispesifiset proteiinit ja niiden käyttömenetelmät
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN113286817B (zh) 2018-09-25 2025-01-28 哈普恩治疗公司 Dll3结合蛋白及使用方法
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2022008519A1 (en) 2020-07-07 2022-01-13 BioNTech SE Therapeutic rna for hpv-positive cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
JP2024525758A (ja) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
US20250179170A1 (en) 2022-03-08 2025-06-05 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
EP4634224A1 (en) 2022-12-14 2025-10-22 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025252553A1 (en) 2024-06-04 2025-12-11 Syngenta Crop Protection Ag Pesticidally-active 2,2-dihalocyclopropyl compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1795187A (zh) * 2003-03-27 2006-06-28 兰肯瑙医学研究所 新型ido抑制剂及其使用方法
WO2007050963A1 (en) * 2005-10-27 2007-05-03 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use thereof
WO2008115804A1 (en) * 2007-03-16 2008-09-25 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use thereof
WO2015140717A1 (en) * 2014-03-18 2015-09-24 Iteos Therapeutics Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509731C2 (sv) 1996-05-14 1999-03-01 Labwell Ab Metod för palladium-katalyserade organiska reaktioner innefattande ett uppvärmningssteg utfört med mikrovågsenergi
JP2000095759A (ja) 1998-07-21 2000-04-04 Takeda Chem Ind Ltd 三環性化合物、その製造法および剤
US6265403B1 (en) 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
MXPA04002070A (es) 2001-09-19 2004-06-07 Pharmacia Corp Compuestos de indazol sustituidos para el tratamiento de la inflamacion.
CN100338062C (zh) 2002-03-28 2007-09-19 卫材株式会社 作为c－Jun N－末端激酶抑制剂的氮杂吲哚类化合物
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
FR2845996A1 (fr) 2002-10-16 2004-04-23 Servier Lab Nouveaux derives de[3,4-a:3,4-c]carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2004093871A1 (en) * 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Novel methods for the treatment of cancer
FR2862647B1 (fr) 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
GB0328909D0 (en) 2003-12-12 2004-01-14 Syngenta Participations Ag Chemical compounds
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
US7405215B2 (en) * 2004-09-21 2008-07-29 Wyeth Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof
MX2007009649A (es) 2005-02-09 2007-11-15 Arqule Inc Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
WO2007039580A1 (en) 2005-10-05 2007-04-12 Nycomed Gmbh Imidazolyl-substituted benzophenone compounds
WO2007045622A1 (en) 2005-10-18 2007-04-26 Nycomed Gmbh Oxazolo [4 , 5-b] pyridine compounds as nitric oxide synthase inhibitors
ES2399112T3 (es) 2006-01-24 2013-03-25 Eli Lilly & Company Moduladores de INDOLSUFONAMIDA de receptores de PROGESTERONA
WO2007117465A2 (en) 2006-03-31 2007-10-18 Abbott Laboratories Indazole compounds
BRPI0709750A2 (pt) 2006-04-05 2011-07-26 Novartis Ag combinaÇÕes de agentes terapÊuticos para tratamento de cÂncer
GB0624308D0 (en) 2006-12-05 2007-01-17 Molmed Spa Combination product
WO2008073306A1 (en) 2006-12-07 2008-06-19 Novartis Ag Organic compounds
NZ578744A (en) 2007-01-31 2012-02-24 Vertex Pharma 2-aminopyridine derivatives useful as kinase inhibitors
EP2183217A2 (en) 2007-07-25 2010-05-12 Boehringer Ingelheim International GmbH Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7868001B2 (en) 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
WO2009073497A2 (en) 2007-11-30 2009-06-11 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
EA020114B1 (ru) 2008-03-24 2014-08-29 Новартис Аг Производные арилсульфонамида в качестве ингибиторов матриксной металлопротеазы
WO2010008427A1 (en) 2008-04-11 2010-01-21 Ludwig Institute For Cancer Research Ltd. Tryptophan catabolism in cancer treatment and diagnosis
DK2315756T5 (en) * 2008-07-08 2015-08-03 Incyte Corp 1,2,5-oxadiazoles as inhibitors of indoleamine-2,3-dioxygenase
DE102008052943A1 (de) 2008-10-23 2010-04-29 Merck Patent Gmbh Azaindolderivate
PE20110819A1 (es) 2008-12-19 2011-11-02 Bristol Myers Squibb Co Compuestos de carbazol carboxamida utiles como inhibidores de cinasa
MX2011008645A (es) 2009-02-17 2011-09-30 Vertex Pharma Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
CA2772371A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
CA2775133A1 (en) 2009-09-23 2011-03-31 Medivation Technologies, Inc. Pyrido[3,4-b]indoles and methods of use
WO2011045224A1 (de) 2009-10-12 2011-04-21 Bayer Cropscience Ag 1- (pyrid-3-yl) -pyrazole und 1- (pyrimid-5-yl) -pyrazole als schädlingsbekämpfungsmittel
CN102656141B (zh) 2009-10-13 2016-04-06 利亘制药公司 模拟造血生长因子的小分子化合物及其用途
JP6261340B2 (ja) 2010-11-18 2018-01-17 リガンド ファーマシューティカルズ インコーポレイテッド 造血成長因子模倣体の使用
AU2012230890A1 (en) 2011-03-22 2013-09-26 Amgen Inc. Azole compounds as Pim inhibitors
DK2714677T3 (en) 2011-05-23 2018-11-26 Merck Patent Gmbh PYRIDINE AND PYRAZINE DERIVATIVES
WO2013025883A1 (en) 2011-08-17 2013-02-21 Amgen Inc. Heteroaryl sodium channel inhibitors
US20160263087A1 (en) 2013-11-08 2016-09-15 Iteos Therapeutics Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
US9126984B2 (en) 2013-11-08 2015-09-08 Iteos Therapeutics 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
JP2017505346A (ja) 2014-02-12 2017-02-16 アイティーオス セラペウティクス 新規な３−（インドール−３−イル）−ピリジン誘導体、医薬組成物、および使用方法
US20150266857A1 (en) * 2014-03-18 2015-09-24 Iteos Therapeutics Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
UY36122A (es) 2014-05-15 2016-01-08 Iteos Therapeutics ?derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1?
CA2994917A1 (en) * 2015-08-10 2017-02-16 Pfizer Inc. 3-indol substituted derivatives, pharmaceutical compositions and methods for use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1795187A (zh) * 2003-03-27 2006-06-28 兰肯瑙医学研究所 新型ido抑制剂及其使用方法
WO2007050963A1 (en) * 2005-10-27 2007-05-03 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use thereof
WO2008115804A1 (en) * 2007-03-16 2008-09-25 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use thereof
WO2015140717A1 (en) * 2014-03-18 2015-09-24 Iteos Therapeutics Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EDUARD DOLUSI,ET AL.: "Tryptophan 2,3-Dioxygenase (TDO) Inhibitors.3-(2-(Pyridyl)ethenyl)indoles as Potential Anticancer Immunomodulators", 《J. MED. CHEM.》 *
EDUARD DOLUSIC，ET AL.: "Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008-2012)", 《EXPERT OPIN. THER. PATENTS》 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111166735A (zh) * 2020-01-15 2020-05-19 延边大学 邻苯二甲酸-双-(2-乙基庚基)酯在抑制脂肪蓄积中的应用
CN111166735B (zh) * 2020-01-15 2023-08-18 延边大学 邻苯二甲酸-双-(2-乙基庚基)酯在抑制脂肪蓄积中的应用
CN111499592A (zh) * 2020-03-14 2020-08-07 江苏省农用激素工程技术研究中心有限公司 5-氨甲基糖精的合成方法
CN111499592B (zh) * 2020-03-14 2023-06-23 江苏省农用激素工程技术研究中心有限公司 5-氨甲基糖精的合成方法
WO2021218912A1 (zh) * 2020-04-30 2021-11-04 南京明德新药研发有限公司 含苯基并内磺酰胺的化合物
CN115443274A (zh) * 2020-04-30 2022-12-06 南京明德新药研发有限公司 含苯基并内磺酰胺的化合物
AU2021262977B2 (en) * 2020-04-30 2023-07-13 Suzhou Genhouse Bio Co., Ltd. Compounds containing benzosultam
US11718610B2 (en) 2020-04-30 2023-08-08 Medshine Discovery Inc. Compounds containing benzosultam
CN115443274B (zh) * 2020-04-30 2025-04-25 勤浩医药（苏州）有限公司 含苯基并内磺酰胺的化合物
CN111777557A (zh) * 2020-07-28 2020-10-16 中国科学院上海有机化学研究所 以芳香联苯烯为骨架的新型抗肿瘤先导化合物及其应用
CN111777557B (zh) * 2020-07-28 2022-11-22 中国科学院上海有机化学研究所 以芳香联苯烯为骨架的新型抗肿瘤先导化合物及其应用
CN119707855A (zh) * 2024-12-20 2025-03-28 西南大学 一种光学活性胺类衍生物及其不对称烷基化合成方法和应用

Also Published As

Publication number Publication date
AU2016231832A1 (en) 2017-09-14
US20160272628A1 (en) 2016-09-22
SG11201706992TA (en) 2017-09-28
RU2672252C1 (ru) 2018-11-13
IL254124A0 (en) 2017-10-31
US9873690B2 (en) 2018-01-23
JP2018511587A (ja) 2018-04-26
JP6775516B2 (ja) 2020-10-28
KR102013512B1 (ko) 2019-08-22
WO2016147144A1 (en) 2016-09-22
KR20170132204A (ko) 2017-12-01
EP3271354A1 (en) 2018-01-24
BR112017019699A2 (pt) 2018-09-04
MX2017011951A (es) 2018-06-15
AU2016231832B2 (en) 2019-09-19
CA2979616A1 (en) 2016-09-22
CA2979616C (en) 2020-04-28
HK1243999A1 (zh) 2018-07-27

Similar Documents

Publication Publication Date Title
CN107635990A (zh) 新型3‑吲哚取代的衍生物、药物组合物及使用方法
TWI494317B (zh) 磺醯胺衍生物
US10544095B2 (en) 3-indol substituted derivatives, pharmaceutical compositions and methods for use
CN101801965B (zh) 作为细胞坏死抑制剂的吲哚化合物
CN103339111B (zh) 双环乙酰基-CoA羧化酶抑制剂
CN101641360B (zh) 哌嗪类衍生物，其制备方法及其在医药上的应用
CN109111451B (zh) 二氢嘧啶类化合物及其在药物中的应用
CN111448199A (zh) 具有抗乙型肝炎病毒(hbv)活性的新的高活性的氨基-噻唑取代的吲哚-2-甲酰胺
CN104902885A (zh) 氨磺酰基-芳基酰胺和其作为药物用于治疗乙型肝炎的用途
JP2017507983A (ja) 新規な３−インドール置換誘導体、医薬組成物、および使用方法
CN106488919B (zh) 3-取代的2-氨基吲哚衍生物
CN111434655A (zh) 溶血磷脂酸受体拮抗剂及其制备方法
WO2024088408A1 (zh) 一种含氮杂环化合物、其药学上可接受的盐及其制备方法与应用
CN114409656B (zh) Pim激酶抑制剂
WO2022222963A1 (zh) 含咪唑稠环类衍生物、其制备方法及其在医药上的应用
TW202320766A (zh) 一類具有吡啶并六員環結構的ｓｏｓ１抑制劑
CN109476637B (zh) 杂环脯氨酰胺衍生物
KR20050044497A (ko) 올리고펩티드 및 카텝신 ｓ 억제제로서 이를 포함하는조성물
HK40121452A (zh) 新型哌嗪衍生物或其盐及医药组合物
CN101365680A (zh) 作为肾素抑制剂的3,5-取代的哌啶化合物
WO2025051161A1 (zh) 用于治疗或预防冠状病毒感染的3cl蛋白酶抑制剂及其用途
CN117396462A (zh) 抗病毒化合物
CN119855589A (zh) 杂环pad4抑制剂
WO2022048684A1 (zh) Jnk抑制剂、其药物组合物和用途
CN113795486A (zh) 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1243999

Country of ref document: HK

AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20210709

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1243999

Country of ref document: HK